--- title: "Solbinsiran | PepTracker Pro" url: https://peptrackerpro.com/peptides/solbinsiran description: "An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Eli Lilly that lowers atherogenic lipids by silencing ANGPTL3 (angiopoietin-like protein 3), a liver-made brake on the fat-clearing enzymes lipoprotein lipase and endothelial lipase. By switching off ANGPTL3 production in the liver, solbinsiran simultaneously reduces both triglyceride-rich remnant particles and LDL cholesterol - the two lipid drivers of atherosclerotic cardiovascular disease. In the Phase 2 PROLONG-ANG3 trial (The Lancet, 2025; 205 adults with mixed dyslipidemia on statins), the 400 mg dose given only twice, three months apart, lowered apolipoprotein B (apoB) by a placebo-adjusted ~14% at day 180, with reductions sustained to day 270 and a ~28% fall in liver fat. Designed for infrequent dosing and built to avoid the liver toxicity that ended earlier ANGPTL3 antisense drugs, solbinsiran is positioned as the foundation for a planned Phase 3 cardiovascular outcomes program." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Solbinsiran Medium Evidence An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Eli Lilly that lowers atherogenic lipids by silencing ANGPTL3 (angiopoietin-like protein 3), a liver-made brake on the fat-clearing enzymes lipoprotein lipase and endothelial lipase. By switching off ANGPTL3 production in the liver, solbinsiran simultaneously reduces both triglyceride-rich remnant particles and LDL cholesterol - the two lipid drivers of atherosclerotic cardiovascular disease. In the Phase 2 PROLONG-ANG3 trial (The Lancet, 2025; 205 adults with mixed dyslipidemia on statins), the 400 mg dose given only twice, three months apart, lowered apolipoprotein B (apoB) by a placebo-adjusted ~14% at day 180, with reductions sustained to day 270 and a ~28% fall in liver fat. Designed for infrequent dosing and built to avoid the liver toxicity that ended earlier ANGPTL3 antisense drugs, solbinsiran is positioned as the foundation for a planned Phase 3 cardiovascular outcomes program. Aliases LY3561774 +3 more Evidence Medium Evidence Last Updated 2026-08-16 Reading Time 5 min ## What It Is Solbinsiran (development code LY3561774) is a GalNAc-conjugated small interfering RNA (siRNA) developed by Eli Lilly and Company that targets the messenger RNA for ANGPTL3 (angiopoietin-like protein 3) in the liver. ANGPTL3 is a hepatocyte-made protein that acts as a brake on two fat-clearing enzymes - lipoprotein lipase and endothelial lipase - so when it is silenced, the body clears triglyceride-rich lipoproteins and their cholesterol-laden remnants more efficiently and also lowers LDL cholesterol. Because the siRNA is attached to GalNAc (N-acetylgalactosamine), a sugar tag recognized by the asialoglycoprotein receptor found almost exclusively on liver cells, the drug concentrates in the hepatocytes where ANGPTL3 is produced, allowing a small subcutaneous injection to be given only once every few months. Human genetics support the target: people who naturally carry loss-of-function ANGPTL3 variants have low triglycerides and LDL cholesterol and appear protected from coronary artery disease. Solbinsiran is being developed primarily for mixed dyslipidemia - the common combination of high triglycerides and elevated LDL cholesterol that raises the risk of atherosclerotic cardiovascular disease (ASCVD) - where its ability to lower both lipid fractions at once with an infrequent injection is the central appeal. It is closely related to Arrowhead's zodasiran, the other clinical-stage ANGPTL3 siRNA, but is aimed at the larger statin-treated ASCVD-risk population rather than at rare homozygous familial hypercholesterolemia. Solbinsiran is investigational and not approved for any use; it is a laboratory-made oligonucleotide medicine given only in clinical trials, not a dietary supplement or research chemical. Also known as: LY3561774, Lilly ANGPTL3 siRNA, GalNAc ANGPTL3 siRNA, anti-ANGPTL3 RNAi (Lilly) ## Regulatory Status Investigational (Phase 2 complete; Phase 3 planned; not approved) Solbinsiran has not been approved by the FDA or any regulator; it remains investigational. Eli Lilly evaluated it in the Phase 2 PROLONG-ANG3 study in adults with mixed dyslipidemia on statins (double-blind, randomized, placebo-controlled; 205 participants; subcutaneous dosing on day 0 and day 90 with follow-up to at least day 270), where the 400 mg dose met the primary apoB-lowering endpoint. Lilly has said the efficacy and safety data set the foundation for a Phase 3 cardiovascular outcomes trial, and a Phase 2 study in hypertriglyceridemia has also been initiated. Solbinsiran is developed by Eli Lilly and Company (development code LY3561774). ## Why Researchers Study It Most people who have heart attacks and strokes have both elevated LDL cholesterol and elevated triglycerides, yet common therapies mainly target one at a time and many statin-treated patients still have residual risk from triglyceride-rich remnant particles. Solbinsiran is interesting because it lowers both LDL and triglycerides at once by silencing a single upstream liver protein, ANGPTL3, that normally slows the clearance of fat from the blood. The target has unusual human validation: people born with naturally low ANGPTL3 run low triglycerides and LDL cholesterol and appear protected from coronary disease, so mimicking that genetic state with an occasional injection is an appealing strategy. Solbinsiran is also a case study in drug design - earlier attempts to inhibit ANGPTL3 with an antisense oligonucleotide (vupanorsen) were abandoned over dose-dependent liver-fat and enzyme problems, and solbinsiran's GalNAc-siRNA chemistry is meant to deliver deep, durable silencing at low doses without that toxicity; in PROLONG-ANG3 it actually reduced liver fat and was as well tolerated as placebo. Scientifically it extends the GalNAc-siRNA cardiometabolic platform (already aimed at Lp(a), apoC-III and angiotensinogen with drugs like olpasiran, plozasiran, olezarsen and zilebesiran) to the ANGPTL3 target, and its infrequent dosing and dual LDL-plus-triglyceride effect make it a leading candidate to test whether ANGPTL3 lowering prevents cardiovascular events in the broad statin-treated population - a question a large Phase 3 outcomes trial is being built to answer. ## Proposed Mechanisms - GalNAc-conjugated small interfering RNA (siRNA) that binds and triggers degradation of the messenger RNA encoding ANGPTL3 (angiopoietin-like protein 3) in hepatocytes, reducing production of the protein by roughly 90% - ANGPTL3 normally inhibits lipoprotein lipase and endothelial lipase; lowering it releases those enzymes to clear triglyceride-rich lipoproteins and remnant cholesterol from the circulation more efficiently - Simultaneously lowers LDL cholesterol and apolipoprotein B (apoB), reducing both of the atherogenic lipoprotein fractions that drive atherosclerotic cardiovascular disease - GalNAc (N-acetylgalactosamine) conjugation targets the asialoglycoprotein receptor on liver cells, concentrating the siRNA in the liver and enabling a low-dose subcutaneous injection given only once every few months - Recapitulates the low-lipid, apparently cardioprotective state seen in people who naturally carry loss-of-function ANGPTL3 gene variants ## Evidence Snapshot Medium Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Phase 2 (PROLONG-ANG3, The Lancet 2025) | 205 adults with mixed dyslipidemia (fasting triglycerides ~150-500 mg/dL, elevated LDL and non-HDL cholesterol) on moderate- or high-intensity statins, at 41 sites in seven countries; randomized 1:2:2:2 to subcutaneous solbinsiran 100 mg, 400 mg, 800 mg or placebo on day 0 and day 90, followed to at least day 270 | Primary endpoint (placebo-adjusted percent change in apoB at day 180) was -14.3% for solbinsiran 400 mg (95% CI -23.6 to -3.9; P=0.0085), the only dose reaching statistical significance; -2.8% (100 mg) and -8.3% (800 mg) were not significant. ApoB reductions of roughly 11% were sustained across doses to day 270; the 400 mg dose lowered hepatic fat fraction by about 28%; treatment-emergent adverse events were no more frequent than placebo (52% at 400 mg vs 65% placebo) | Source | | Phase 1 / early human (JACC 2025) | Preclinical models and first-in-human single- and repeat-dose studies in adults with elevated lipids; subcutaneous GalNAc-siRNA | Repeat dosing produced ANGPTL3 reductions of about 89% (+/-6%), triglyceride reductions up to about 70% (+/-13%) and LDL cholesterol reductions up to about 42% (+/-14%), with simultaneous lowering of triglyceride-rich remnants and LDL particles and no dose-dependent hepatotoxicity | Source | | Phase 3 (cardiovascular outcomes; planned) | Planned large randomized cardiovascular outcomes program in higher-risk patients with atherogenic dyslipidemia, using the 400 mg lead dose; a separate Phase 2 study in hypertriglyceridemia has also been initiated | Designed to test whether ANGPTL3 lowering with solbinsiran reduces cardiovascular events; results not yet available | Source | ## Commonly Discussed Benefits Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Cholesterol Management: https://peptrackerpro.com/benefits/cholesterol-management Disease Modification: https://peptrackerpro.com/benefits/disease-modification Researching Solbinsiran? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=solbinsiran) ## Safety & Cautions - Solbinsiran is investigational and not approved for any use; efficacy and safety data come from Phase 1 and Phase 2 trials, and cardiovascular outcome benefit has not been established - Because it produces deep, long-lasting silencing of ANGPTL3, the effect of a dose takes months to wear off and cannot be quickly reversed - ANGPTL3 lowering sits at the crossroads of fat and glucose handling; although PROLONG-ANG3 reduced liver fat and was well tolerated, long-term metabolic effects are still being characterized - Injection-site reactions and common infections were among the adverse events reported with the GalNAc-siRNA class; solbinsiran's overall adverse-event rate was similar to placebo in Phase 2 - It is an injectable investigational oligonucleotide biologic used only under medical supervision in clinical trials; it is not a supplement or research chemical, and any 'solbinsiran' or 'LY3561774' offered by a vendor is unverified and unsafe - As with any lipid-lowering agent in development, use in pregnancy has not been established and appropriate precautions apply in clinical trials ## Comparisons See how Solbinsiran compares to related peptides: Solbinsiran vs Eplontersen: https://peptrackerpro.com/compare/solbinsiran-vs-eplontersen Solbinsiran vs Inclisiran: https://peptrackerpro.com/compare/solbinsiran-vs-inclisiran Solbinsiran vs Lepodisiran: https://peptrackerpro.com/compare/solbinsiran-vs-lepodisiran Solbinsiran vs Muvalaplin: https://peptrackerpro.com/compare/solbinsiran-vs-muvalaplin Solbinsiran vs Obicetrapib: https://peptrackerpro.com/compare/solbinsiran-vs-obicetrapib Solbinsiran vs Olezarsen: https://peptrackerpro.com/compare/solbinsiran-vs-olezarsen Solbinsiran vs Olpasiran: https://peptrackerpro.com/compare/solbinsiran-vs-olpasiran Solbinsiran vs Pelacarsen: https://peptrackerpro.com/compare/solbinsiran-vs-pelacarsen Solbinsiran vs Plozasiran: https://peptrackerpro.com/compare/solbinsiran-vs-plozasiran Solbinsiran vs Vutrisiran: https://peptrackerpro.com/compare/solbinsiran-vs-vutrisiran Solbinsiran vs Zerlasiran: https://peptrackerpro.com/compare/solbinsiran-vs-zerlasiran Solbinsiran vs Zilebesiran: https://peptrackerpro.com/compare/solbinsiran-vs-zilebesiran Solbinsiran vs Zodasiran: https://peptrackerpro.com/compare/solbinsiran-vs-zodasiran ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Ray KK, et al. - Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial, The Lancet (2025) PubMed (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00507-0/fulltext) 2. [2] Ray KK, Linnebjerg H, Michael LF, et al. - Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies, JACC (2025) PubMed (https://www.jacc.org/doi/10.1016/j.jacc.2025.03.005) 3. [3] PROLONG-ANG3 (solbinsiran, phase 2 trial) - PubMed record PubMed (https://pubmed.ncbi.nlm.nih.gov/40179932/) 4. [4] Solbinsiran Significantly Reduces apoB in Mixed Dyslipidemia in Phase 2 Trial - HCPLive (ACC.25 coverage) PubMed (https://www.hcplive.com/view/solbinsiran-significantly-reduces-apob-in-mixed-dyslipidemia-in-phase-2-trial) 5. [5] Eli Lilly's siRNA Lowers Key Cardiovascular Disease Biomarkers in Phase II Mixed Dyslipidemia Trial - Precision Medicine Online PubMed (https://www.precisionmedicineonline.com/cardiovascular-disease/eli-lillys-sirna-lowers-key-cardiovascular-disease-biomarkers-phase-ii-mixed) ### Keep researching in the app - Log Solbinsiran to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=solbinsiran Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### Eplontersen High Evidence An approved, once-monthly, self-administered subcutaneous GalNAc-conjugated antisense oligonucleotide (ASO) from Ionis and AstraZeneca that treats transthyretin-mediated (ATTR) amyloidosis by lowering the liver's production of transthyretin (TTR). Transthyretin is a liver-made transport protein that can misfold and deposit as amyloid in nerves and the heart; eplontersen is a short synthetic strand of chemically modified DNA/RNA that binds TTR messenger RNA and directs its enzymatic (RNase H1) degradation before the protein is made, cutting circulating TTR by roughly 80%. A triantennary N-acetylgalactosamine (GalNAc) tag delivers it to liver cells, allowing a low-dose 45 mg injection just once a month via autoinjector or pre-filled syringe. Marketed as Wainua (US) and Wainzua (EU), it was FDA-approved in December 2023 for the polyneuropathy of hereditary ATTR amyloidosis (ATTRv-PN) on the strength of the NEURO-TTRansform trial, and is now approved in more than 20 countries. Eplontersen is the antisense (ASO) counterpart to the siRNA drug vutrisiran (Amvuttra): both silence TTR, and both were tested in ATTR cardiomyopathy - but where vutrisiran's HELIOS-B trial succeeded on top of a stabilizer background, eplontersen's much larger CARDIO-TTRansform cardiomyopathy trial missed its primary endpoint in July 2026, with a benefit seen only in the prespecified monotherapy subgroup. It is a GalNAc-ASO sibling of Ionis's olezarsen and pelacarsen and the second-generation successor to the earlier, non-GalNAc TTR antisense drug inotersen (Tegsedi). Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Disease Modification: https://peptrackerpro.com/benefits/disease-modification Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular View Details: https://peptrackerpro.com/peptides/eplontersen \+ Compare: https://peptrackerpro.com/compare?select=eplontersen Track in App: https://app.peptrackerpro.com/?add=eplontersen ### Inclisiran High Evidence An approved, twice-yearly subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Novartis (originally discovered by Alnylam) that lowers LDL cholesterol by silencing PCSK9 (proprotein convertase subtilisin/kexin type 9), the liver protein that destroys LDL receptors. By switching off PCSK9 production inside hepatocytes, inclisiran leaves more LDL receptors on the liver surface to pull LDL cholesterol out of the blood - achieving roughly a 50% LDL reduction with an injection given only twice a year after a loading dose. Marketed as Leqvio, it was the first siRNA medicine approved for a chronic cardiovascular condition: the EU cleared it in December 2020 and the FDA in December 2021, and in July 2025 the FDA expanded the U.S. label to first-line monotherapy, dropping the requirement that it be added on top of a statin. Its Phase 3 ORION-9, ORION-10 and ORION-11 trials established the LDL benefit; a large cardiovascular outcomes program (VICTORION-2-PREVENT and others) is still running to test whether that LDL lowering prevents heart attacks and strokes. Inclisiran is the approved, real-world proof-of-concept for the GalNAc-siRNA cardiometabolic platform that newer investigational agents like zodasiran, solbinsiran, olpasiran and plozasiran build on. View Details: https://peptrackerpro.com/peptides/inclisiran \+ Compare: https://peptrackerpro.com/compare?select=inclisiran Track in App: https://app.peptrackerpro.com/?add=inclisiran ### Lepodisiran Medium Evidence An investigational, long-duration injectable small interfering RNA (siRNA) from Eli Lilly that lowers lipoprotein(a) [Lp(a)] by nearly 94% by silencing the LPA gene in the liver. A single dose keeps Lp(a) suppressed for a year or more, and its Phase 3 ACCLAIM-Lp(a) trial (~12,500 patients) is the first Lp(a) outcomes trial to include people who have not yet had a cardiovascular event. View Details: https://peptrackerpro.com/peptides/lepodisiran \+ Compare: https://peptrackerpro.com/compare?select=lepodisiran Track in App: https://app.peptrackerpro.com/?add=lepodisiran ### Muvalaplin Medium Evidence The first oral, small-molecule inhibitor of lipoprotein(a) [Lp(a)] formation, from Eli Lilly. Instead of silencing a gene, muvalaplin is a once-daily pill that physically blocks apolipoprotein(a) from binding apolipoprotein B — the first step in building an Lp(a) particle. In its Phase 2 KRAKEN trial (published in JAMA, 2024) it cut Lp(a) by up to ~86% (placebo-adjusted) and, as of 2026, is the only Lp(a)-lowering drug that is both oral and already enrolling a large Phase 3 cardiovascular outcomes trial (MOVE-Lp(a)). View Details: https://peptrackerpro.com/peptides/muvalaplin \+ Compare: https://peptrackerpro.com/compare?select=muvalaplin Track in App: https://app.peptrackerpro.com/?add=muvalaplin ### Obicetrapib Medium Evidence An investigational once-daily oral, highly selective CETP (cholesteryl ester transfer protein) inhibitor from NewAmsterdam Pharma (European partner Menarini) that lowers LDL cholesterol and lipoprotein(a) [Lp(a)] in a single pill. Unlike the failed first-generation CETP inhibitors, obicetrapib is valued for LDL and Lp(a) lowering rather than HDL raising. In Phase 3 it cut LDL-C by about a third as monotherapy (BROADWAY) and by roughly half combined with ezetimibe (TANDEM), and reduced Lp(a) by ~33% - published in NEJM and The Lancet (2025). It received a positive EMA CHMP opinion in July 2026 (as Ubeslo and Evlarco), with the PREVAIL cardiovascular outcomes trial due to report in 2026. View Details: https://peptrackerpro.com/peptides/obicetrapib \+ Compare: https://peptrackerpro.com/compare?select=obicetrapib Track in App: https://app.peptrackerpro.com/?add=obicetrapib ### Olezarsen High Evidence An FDA-approved subcutaneous antisense oligonucleotide (ASO) from Ionis Pharmaceuticals, branded Tryngolza, that lowers triglycerides by silencing the messenger RNA for apolipoprotein C-III (apoC-III). Self-injected once a month, it was the first-ever therapy approved for familial chylomicronemia syndrome (FCS) on December 19, 2024, and on June 24, 2026 it became the first and only treatment approved to reduce both triglycerides and the risk of acute pancreatitis in the far larger severe hypertriglyceridemia (sHTG) population. View Details: https://peptrackerpro.com/peptides/olezarsen \+ Compare: https://peptrackerpro.com/compare?select=olezarsen Track in App: https://app.peptrackerpro.com/?add=olezarsen ### Olpasiran Medium Evidence An investigational, once-every-12-weeks injectable small interfering RNA (siRNA) from Amgen that lowers lipoprotein(a) [Lp(a)] by up to ~97% by silencing the LPA gene in the liver. Its Phase 3 OCEAN(a)-Outcomes cardiovascular outcomes trial (~7,000 patients) is one of the pivotal readouts — due December 2026 — that will help decide whether lowering Lp(a) prevents heart attacks and strokes. View Details: https://peptrackerpro.com/peptides/olpasiran \+ Compare: https://peptrackerpro.com/compare?select=olpasiran Track in App: https://app.peptrackerpro.com/?add=olpasiran ### Pelacarsen Medium Evidence A first-in-class, once-monthly injectable antisense oligonucleotide (ASO) from Ionis and Novartis that lowers lipoprotein(a) [Lp(a)] by shutting down apolipoprotein(a) production in the liver. Its pivotal Lp(a)HORIZON trial (8,323 patients) is the first-ever cardiovascular outcomes trial for any Lp(a)-lowering drug, with a landmark topline readout due in 2026. View Details: https://peptrackerpro.com/peptides/pelacarsen \+ Compare: https://peptrackerpro.com/compare?select=pelacarsen Track in App: https://app.peptrackerpro.com/?add=pelacarsen ### Plozasiran High Evidence An approved subcutaneous RNA interference (RNAi) therapy from Arrowhead Pharmaceuticals, branded Redemplo, that silences the gene for apolipoprotein C-III (apoC-III) to lower triglycerides. Given once every three months, it cut triglycerides by roughly 80% in familial chylomicronemia syndrome (FCS) and sharply reduced acute pancreatitis events. The FDA approved it on November 18, 2025 for FCS, and Phase 3 SHASTA-3 and SHASTA-4 (reported July 2026) extended those results to the far larger severe hypertriglyceridemia population. View Details: https://peptrackerpro.com/peptides/plozasiran \+ Compare: https://peptrackerpro.com/compare?select=plozasiran Track in App: https://app.peptrackerpro.com/?add=plozasiran ### Vutrisiran High Evidence An approved, quarterly (once-every-three-months) subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Alnylam that treats transthyretin-mediated (ATTR) amyloidosis by silencing the TTR gene in the liver. Transthyretin is a liver-made transport protein that can misfold and pile up as amyloid deposits in nerves and, critically, the heart; vutrisiran uses RNA interference (RNAi) to degrade both mutant and wild-type TTR messenger RNA before the protein is made, lowering circulating TTR by roughly 80% and starving the amyloid of its raw material. Marketed as Amvuttra, it was first FDA-approved in June 2022 for the polyneuropathy of hereditary ATTR amyloidosis (HELIOS-A), and in March 2025 the FDA expanded the label to ATTR cardiomyopathy (ATTR-CM) of wild-type or hereditary disease - making vutrisiran the first RNAi therapeutic shown to reduce cardiovascular death and cardiovascular events, on the strength of the HELIOS-B outcomes trial. It shares the exact GalNAc-siRNA delivery platform that underlies the cardiometabolic RNAi medicine inclisiran and the investigational agents olpasiran, lepodisiran, zerlasiran, zilebesiran, zodasiran, solbinsiran and plozasiran, and it is the direct successor to Alnylam's earlier intravenous TTR siRNA patisiran (Onpattro). Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Disease Modification: https://peptrackerpro.com/benefits/disease-modification Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment View Details: https://peptrackerpro.com/peptides/vutrisiran \+ Compare: https://peptrackerpro.com/compare?select=vutrisiran Track in App: https://app.peptrackerpro.com/?add=vutrisiran ### Zerlasiran Medium Evidence An investigational, long-acting injectable small interfering RNA (siRNA) from Silence Therapeutics that lowers lipoprotein(a) [Lp(a)] by more than 80% by silencing the LPA gene in the liver. Dosed only every 16–24 weeks, it produced durable ~90% reductions in its Phase 2 ALPACAR-360 trial (published in JAMA, 2024); as of 2026 the company is seeking a partner before starting its Phase 3 cardiovascular outcomes study. View Details: https://peptrackerpro.com/peptides/zerlasiran \+ Compare: https://peptrackerpro.com/compare?select=zerlasiran Track in App: https://app.peptrackerpro.com/?add=zerlasiran ### Zilebesiran Medium Evidence An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Alnylam Pharmaceuticals and Roche/Genentech that lowers blood pressure by silencing angiotensinogen (AGT), the single upstream precursor of the renin-angiotensin-aldosterone system (RAAS). Designed for dosing as infrequently as once or twice a year, it is the first RNА interference (RNAi) therapeutic developed for hypertension. In Phase 2 KARDIA-1 and KARDIA-2 trials it produced durable, clinically meaningful reductions in systolic blood pressure sustained for up to 6 months from a single dose, and in 2025 it advanced into the large Phase 3 ZENITH cardiovascular outcomes trial. Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Disease Modification: https://peptrackerpro.com/benefits/disease-modification View Details: https://peptrackerpro.com/peptides/zilebesiran \+ Compare: https://peptrackerpro.com/compare?select=zilebesiran Track in App: https://app.peptrackerpro.com/?add=zilebesiran ### Zodasiran Medium Evidence An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Arrowhead Pharmaceuticals that lowers atherogenic lipids by silencing ANGPTL3 (angiopoietin-like protein 3), a liver-made regulator of fat metabolism. By switching off ANGPTL3 production, zodasiran deeply reduces triglycerides, remnant cholesterol and LDL cholesterol through a pathway that does not depend on the LDL receptor - making it especially relevant for people, such as those with homozygous familial hypercholesterolemia (HoFH), whose LDL receptors barely work. In the Phase 2b ARCHES-2 trial (NEJM 2024) it produced durable, dose-dependent reductions in triglycerides, remnant cholesterol and ANGPTL3, and in the Phase 2 GATEWAY study it lowered LDL cholesterol by about 40% in HoFH. It is now in the Phase 3 YOSEMITE trial in HoFH, which completed enrollment in July 2026. View Details: https://peptrackerpro.com/peptides/zodasiran \+ Compare: https://peptrackerpro.com/compare?select=zodasiran Track in App: https://app.peptrackerpro.com/?add=zodasiran ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Solbinsiran", "description": "An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Eli Lilly that lowers atherogenic lipids by silencing ANGPTL3 (angiopoietin-like protein 3), a liver-made brake on the fat-clearing enzymes lipoprotein lipase and endothelial lipase. By switching off ANGPTL3 production in the liver, solbinsiran simultaneously reduces both triglyceride-rich remnant particles and LDL cholesterol - the two lipid drivers of atherosclerotic cardiovascular disease. In the Phase 2 PROLONG-ANG3 trial (The Lancet, 2025; 205 adults with mixed dyslipidemia on statins), the 400 mg dose given only twice, three months apart, lowered apolipoprotein B (apoB) by a placebo-adjusted ~14% at day 180, with reductions sustained to day 270 and a ~28% fall in liver fat. Designed for infrequent dosing and built to avoid the liver toxicity that ended earlier ANGPTL3 antisense drugs, solbinsiran is positioned as the foundation for a planned Phase 3 cardiovascular outcomes program.", "url": "https://peptrackerpro.com/peptides/solbinsiran", "lastReviewed": "2026-08-16", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Solbinsiran", "item": "https://peptrackerpro.com/peptides/solbinsiran" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People with mixed dyslipidemia (high triglycerides plus elevated LDL cholesterol) who still have residual cardiovascular risk on statins and want to lower both lipid fractions?", "acceptedAnswer": { "@type": "Answer", "text": "Solbinsiran is a research peptide studied in preclinical models. An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Eli Lilly that lowers atherogenic lipids by silencing ANGPTL3 (angiopoietin-like protein 3), a liver-made brake on the fat-clearing enzymes lipoprotein lipase and endothelial lipase. By switching off ANGPTL3 production in the liver, solbinsiran simultaneously reduces both triglyceride-rich remnant particles and LDL cholesterol - the two lipid drivers of atherosclerotic cardiovascular disease. In the Phase 2 PROLONG-ANG3 trial (The Lancet, 2025; 205 adults with mixed dyslipidemia on statins), the 400 mg dose given only twice, three months apart, lowered apolipoprotein B (apoB) by a placebo-adjusted ~14% at day 180, with reductions sustained to day 270 and a ~28% fall in liver fat. Designed for infrequent dosing and built to avoid the liver toxicity that ended earlier ANGPTL3 antisense drugs, solbinsiran is positioned as the foundation for a planned Phase 3 cardiovascular outcomes program." } }, { "@type": "Question", "name": "Patients interested in an infrequent injection - dosed once every few months - rather than daily pills for lipid control?", "acceptedAnswer": { "@type": "Answer", "text": "Solbinsiran is a research peptide studied in preclinical models. An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Eli Lilly that lowers atherogenic lipids by silencing ANGPTL3 (angiopoietin-like protein 3), a liver-made brake on the fat-clearing enzymes lipoprotein lipase and endothelial lipase. By switching off ANGPTL3 production in the liver, solbinsiran simultaneously reduces both triglyceride-rich remnant particles and LDL cholesterol - the two lipid drivers of atherosclerotic cardiovascular disease. In the Phase 2 PROLONG-ANG3 trial (The Lancet, 2025; 205 adults with mixed dyslipidemia on statins), the 400 mg dose given only twice, three months apart, lowered apolipoprotein B (apoB) by a placebo-adjusted ~14% at day 180, with reductions sustained to day 270 and a ~28% fall in liver fat. Designed for infrequent dosing and built to avoid the liver toxicity that ended earlier ANGPTL3 antisense drugs, solbinsiran is positioned as the foundation for a planned Phase 3 cardiovascular outcomes program." } }, { "@type": "Question", "name": "Clinicians and researchers following ANGPTL3-targeted therapies and comparing solbinsiran with the other ANGPTL3 siRNA zodasiran, the antibody evinacumab and discontinued antisense drugs like vupanorsen?", "acceptedAnswer": { "@type": "Answer", "text": "Solbinsiran is a research peptide studied in preclinical models. An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Eli Lilly that lowers atherogenic lipids by silencing ANGPTL3 (angiopoietin-like protein 3), a liver-made brake on the fat-clearing enzymes lipoprotein lipase and endothelial lipase. By switching off ANGPTL3 production in the liver, solbinsiran simultaneously reduces both triglyceride-rich remnant particles and LDL cholesterol - the two lipid drivers of atherosclerotic cardiovascular disease. In the Phase 2 PROLONG-ANG3 trial (The Lancet, 2025; 205 adults with mixed dyslipidemia on statins), the 400 mg dose given only twice, three months apart, lowered apolipoprotein B (apoB) by a placebo-adjusted ~14% at day 180, with reductions sustained to day 270 and a ~28% fall in liver fat. Designed for infrequent dosing and built to avoid the liver toxicity that ended earlier ANGPTL3 antisense drugs, solbinsiran is positioned as the foundation for a planned Phase 3 cardiovascular outcomes program." } }, { "@type": "Question", "name": "People tracking RNA interference (RNAi) and GalNAc-siRNA cardiometabolic medicines such as zodasiran, olpasiran, lepodisiran, zerlasiran, plozasiran, olezarsen and zilebesiran?", "acceptedAnswer": { "@type": "Answer", "text": "Solbinsiran is a research peptide studied in preclinical models. An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Eli Lilly that lowers atherogenic lipids by silencing ANGPTL3 (angiopoietin-like protein 3), a liver-made brake on the fat-clearing enzymes lipoprotein lipase and endothelial lipase. By switching off ANGPTL3 production in the liver, solbinsiran simultaneously reduces both triglyceride-rich remnant particles and LDL cholesterol - the two lipid drivers of atherosclerotic cardiovascular disease. In the Phase 2 PROLONG-ANG3 trial (The Lancet, 2025; 205 adults with mixed dyslipidemia on statins), the 400 mg dose given only twice, three months apart, lowered apolipoprotein B (apoB) by a placebo-adjusted ~14% at day 180, with reductions sustained to day 270 and a ~28% fall in liver fat. Designed for infrequent dosing and built to avoid the liver toxicity that ended earlier ANGPTL3 antisense drugs, solbinsiran is positioned as the foundation for a planned Phase 3 cardiovascular outcomes program." } } ] } ] ```